Overview of mimotopes and related strategies in tumor vaccine development

Expert Review of Vaccines

Volumn 7, Issue 10, 2008, Pages 1547-1555

  Zhao, Lina ^b   Liu, Zhiguo ^b   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Immunotherapy; Neoplasm; Peptide mimotope; Phage display; Tumor vaccine

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD146 ANTIGEN; CD20 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GANGLIOSIDE GD2; MELANOMA ANTIGEN; MG7 ANTIGEN; MIMOTOPE; MONOCLONAL ANTIBODY; PEPTIDE VACCINE; RITUXIMAB; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER RESEARCH; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION;

CANCER VACCINES; EPITOPES; HUMANS; PEPTIDE LIBRARY; VACCINES, SUBUNIT;

EID: 57349183155     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.10.1547     Document Type: Review

References (80)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004).
2. Dalgleish A. Overcoming technical challenges in the development of cancer vaccines. IDrugs 10(7), 463-467 (2007).
3. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21(12), 2415-2432 (2003). • Reviews the immunologic basis of clinical trials and lists a variety of cancer vaccines and ongoing randomized clinical trials.
4. Copier J, Ward S, Dalgleish A. Cell based cancer vaccines: regulatory and commercial development. Vaccine 25(Suppl. 2), B35-B46 (2007).
5. Ward S, Copier J, Dalgleish A. Technical challenges facing therapeutic cancer vaccines. Curr. Opin. Drug Discov. Dev. 11(2), 168-177 (2008).
6. Sharav T, Wiesmuller KH, Walden P. Mimotope vaccines for cancer immunotherapy. Vaccine 25(16), 3032-3037 (2007). •• Summarizes mimotope design approaches, updates information on T-cell specificities and repertoires addressed by mimotopes, as well as clinical tests of mimotope vaccines for cancer immunotherapy.
7. Monzavi-Karbassi B, Pashov A, Jousheghany F, Artaud C, Kieber-Emmons T. Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine. Int. J. Mol. Med. 17(6), 1045-1052 (2006).
8. Hafner C, Wagner S, Jasinska J et al. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization. J. Invest. Dermatol. 124(1), 125-131 (2005).
9. Sette A, Livingston B, McKinney D et al. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 29(3-4), 271-276 (2001).
10. Fan D, Zhang X, Chen X et al. Bird's-eye view on gastric cancer research of the past 25 years. J. Gastroenterol. Hepatol. 20(3), 360-365 (2005). •• Overview of MG antigens of gastric cancer produced by generating monoclonal antibodies and their clinical applications in the diagnosis and treatment of gastric cancer.
11. Felici F, Luzzago A, Folgori A, Cortese R. Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries. Gene 128(1), 21-27 (1993).
12. Scholl I, Wiedermann U, Forster-Waldl E et al. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help. Clin. Exp. Allergy 32(11), 1583-1588 (2002). • Suggests that mimotopes are able to induce antibody responses with the help of bystander T cells.
13. Sidhu SS, Lowman HB, Cunningham BC, Wells JA. Phage display for selection of novel binding peptides. Methods Enzymol. 328, 333-363 (2000).
14. Scott JK , Smith GP. Searching for peptide ligands with an epitope library. Science 249(4967), 386-390 (1990).
15. Parmley SF , Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73(2), 305-318 (1988).
16. Partidos CD. Peptide mimotopes as candidate vaccines. Curr. Opin. Mol. Ther. 2(1), 74-79 (2000).
17. Riemer AB, Klinger M, Wagner S et al. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J. Immunol. 173(1), 394-401 (2004).
18. Irving MB, Pan O, Scott JK. Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr. Opin. Chem. Biol. 5(3), 314-324 (2001).
19. Sherev T, Wiesmuller KH, Walden P. Mimotopes of tumor-associated T-cell epitopes for cancer vaccines determined with combinatorial peptide libraries. Mol. Biotechnol. 25(1), 53-61 (2003).
20. Mond JJ, Vos Q, Lees A, Snapper CM. T cell independent antigens. Curr. Opin. Immunol. 7(3), 349-354 (1995).
21. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491, 369-402 (2001).
22. Chatterjee M, Tainsky MA. Non-traditional immunogens and their application to immunotherapy. Curr. Opin. Mol. Ther. 10(1), 62-67 (2008).
23. Grothaus MC, Srivastava N, Smithson SL et al. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine 18(13), 1253-1263 (2000).
24. Gundlach BR, Wiesmuller KH, Junt T, Kienle S, Jung G, Walden P. Specificity and degeneracy of minor histocompatibility antigen-specific MHC-restricted CTL. J. Immunol. 156(10), 3645-3651 (1996).
25. Riemer AB, Jensen-Jarolim E. Mimotope vaccines: epitope mimics induce anticancer antibodies. Immunology Lett. 113(1), 1-5 (2007). • Update on different vaccination strategies based on the mimotope conception. Lists the advantages of peptide mimics.
26. de Cerio AL, Zabalegui N, Rodriguez-Calvillo M, Inoges S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene 26(25), 3594-3602 (2007).
27. Alfonso M, Diaz A, Hernandez AM et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol. 168(5), 2523-2529 (2002).
28. Mittelman A, Chen ZJ, Kageshita T et al. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular- weight-melanoma-associated antigen monoclonal antibodies. J. Clin. Invest. 86(6), 2136-2144 (1990).
29. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res. 54(2), 415-421 (1994).
30. Mittelman A, Wang X, Matsumoto K, Ferrone S. Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 14(2), 175-181 (1995).
31. Forster-Waldl E, Riemer AB, Dehof AK et al. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol. Immunol. 42(3), 319-325 (2005).
32. Riemer AB, Forster-Waldl E, Bramswig KH et al. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur. J. Immunol. 36(5), 1267-1274 (2006).
33. Fest S, Huebener N, Weixler S et al. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res. 66(21), 10567-10575 (2006).
34. Bolesta E, Kowalczyk A, Wierzbicki A et al. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res. 65(8), 3410-3418 (2005).
35. Kowalczyk A, Wierzbicki A, Gil M et al. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery. Cancer Immunol. Immunother. 56(9), 1443-1458 (2007).
36. Wondimu A, Zhang T, Kieber-Emmons T et al. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol. Immunother. 57(7), 1079-1089 (2008).
37. Hardy B, Indjiia L, Rodionov G, Raiter A, Inbal A. Treatment with monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma. Int. J. Oncol. 19(5), 897-902 (2001).
38. Hardy B, Kovjazin R, Raiter A, Ganor N, Novogrodsky A. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. Proc.Natl Acad. Sci. USA 94(11), 5756-5760 (1997).
39. Hardy B, Yampolski I, Kovjazin R, Galli M, Novogrodsky A. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice. Cancer Res. 54(22), 5793-5796 (1994).
40. Hardy B, Raiter A. A mimotope peptide-based anti-cancer vaccine selected by monoclonal antibody. Vaccine 23(34), 4283-4291 (2005).
41. Feinmesser M, Raiter A, Hardy B. Prevention of melanoma metastases in lungs of treated and peptide immunized mice. Int. J. Oncol. 29(4), 911-917 (2006).
42. Yarden Y , Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127-137 (2001).
43. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J. Natl Cancer Inst. 97(22), 1663-1670 (2005).
44. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198(2-3), 165-184 (1994).
45. Riemer AB, Untersmayr E, Knittelfelder R et al. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res. 67(7), 3406-3411 (2007).
46. Jiang B, Liu W, Qu H et al. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2. J. Biol. Chem. 280(6), 4656-4662 (2005).
47. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J. Lab. Clin. Med. 134(5), 445-450 (1999).
48. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 108(6), 1975-1978 (2006). •• Details generation of peptide mimics for the epitope recognized by rituximab. Identification of such an epitope would trigger further studies, ultimately explaining why rituximab has such powerful effects on B-cell life.
49. Li M, Yan Z, Han W, Zhang Y. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies. Cell. Immunol. 239(2), 136-143 (2006).
50. Li M, Han W, Zhang Q, Xue X, Wang Z, Zhang Y. Development of a mimotope-based vaccine against CD20 antigen. Protein Pept. Lett. 14(6), 610-614 (2007).
51. Perosa F, Favoino E, Caragnano MA, Dammacco F. CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases. Ann. NY Acad. Sci. 1051, 672-683 (2005).
52. Wagner S, Hafner C, Allwardt D et al. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J. Immunol. 174(2), 976-982 (2005).
53. Hafner C, Wagner S, Allwardt D et al. Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity. Melanoma Res. 15(2), 111-117 (2005).
54. Riemer AB, Hantusch B, Sponer B et al. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol. Immunother. 54(7), 677-684 (2005).
55. Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S. Differential immunogenicity of two peptides isolated by high molecular weight-melanoma- associated antigen-specific monoclonal antibodies with different affinities. J. Immunol. 174(11), 7104-7110 (2005).
56. Luo W, Ko E, Hsu JC, Wang X, Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J. Immunol. 176(10), 6046-6054 (2006).
57. Hafner C, Samwald U, Wagner S et al. Selection of mimotopes of the cell surface adhesion molecule Mel-CAM from a random pVIII-28aa phage peptide library. J. Invest. Dermatol. 119(4), 865-869 (2002).
58. Bramswig KH, Knittelfelder R, Gruber S et al. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin.Cancer Res. 13(21), 6501-6508 (2007).
59. Park SH, Bae YM, Kwon HJ et al. JL1, a novel differentiation antigen of human cortical thymocyte. J. Exp. Med. 178(4), 1447-1451 (1993).
60. Shin YK, Choi YL, Choi EY et al. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications. Cancer Immunol. Immunother. 52(8), 506-512 (2003).
61. Chung J, Park S, Kim D et al. Identification of antigenic peptide recognized by the anti-JL1 leukemia-specific monoclonal antibody from combinatorial peptide phage display libraries. J. Cancer Res. Clin. Oncol. 128(12), 641-649 (2002).
62. Xu L, Jin BQ, Fan DM. Selection and identification of mimic epitopes for gastric cancer-associated antigen MG7 Ag. Mol. Cancer Ther. 2(3), 301-306 (2003).
63. Hang QL, Ding J, Gong AC et al. Screening of bioactive peptide that mimic the epitope of gastric cancer associated antigen. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 19(3), 308-310 (2003).
64. Meng FP, Ding J, Yu ZC et al. Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J. Gastroenterol. 11(12), 1833-1836 (2005).
65. Guo CC, Ding J, Pan BR et al. Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhimurium as carrier. World J. Gastroenterol. 9(6), 1191-1195 (2003).
66. Chen Y, Wu K, Guo C et al. A novel DNA vaccine containing four mimicry epitopes for gastric cancer. Cancer Biol. Ther. 4(3), 308-312 (2005).
67. Shi R, Hong L, Wu D et al. Enhanced immune response to gastric cancer specific antigen peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion. Cancer Biol. Ther. 4(2), 218-224 (2005).
68. Zhang D, Chen Y, Fan D. MG7 mimotope-based DNA vaccination for gastric cancer. Expert Rev. Vaccines 5(2), 223-231 (2006). •• Early review regarding the role of mimotope-based DNA vaccines in gastric cancer. Focuses mainly on gastric cancer vaccination based on MG7 mimotopes.
69. Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl Cancer Inst. 94(11), 805-818 (2002).
70. El Kasmi KC, Deroo S, Theisen DM, Brons NH, Muller CP. Crossreactivity of mimotopes and peptide homologues of a sequential epitope with a monoclonal antibody does not predict crossreactive immunogenicity. Vaccine 18(3-4), 284-290 (1999).
71. Weisser NE, Almquist KC, Hall JC. A rAb screening method for improving the probability of identifying peptide mimotopes of carbohydrate antigens. Vaccine 25(23), 4611-4622 (2007).
72. Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F. Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J. Immunol. 179(11), 7967-7974 (2007).
73. Sette A, Livingston B, McKinney D et al. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 29(3-4), 271-276 (2001).
74. Desmezieres E, Jacob Y, Saron MF, Delpeyroux F, Tordo N, Perrin P. Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines. J. Gen. Virol. 80(Pt 9), 2343-2351 (1999).
75. Astori M , Kraehenbuhl JP. Recombinant fusion peptides containing single or multiple repeats of a ubiquitous T-helper epitope are highly immunogenic. Mol. Immunol. 33(13), 1017-1024 (1996).
76. Dadaglio G, Moukrim Z, Lo-Man R, Sheshko V, Sebo P, Leclerc C. Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis. Infect. Immun. 68(7), 3867-3872 (2000).
77. Schreiber H, Wu TH, Nachman J, Kast WM. Immunodominance and tumor escape. Semin. Cancer Biol. 12(1), 25-31 (2002).
78. Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 60(14), 3782-3789 (2000).
79. Walden P. Therapeutic vaccination for the treatment of malignant melanoma. Recent Results Cancer Res. 176, 219-227 (2007).
80. Dalgleish AG, Whelan MA. Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunol. Immunother. 55(8), 1025-1032 (2006). • Reviews the major areas of cancer vaccine research and describes some of the successes and failures, as well as some reasons for Phase III failure.